Back to top
more

Sangamo Therapeutics (SGMO)

(Delayed Data from NSDQ)

$0.55 USD

0.55
3,598,115

-0.01 (-1.78%)

Updated May 13, 2024 04:00 PM ET

After-Market: $0.55 0.00 (-0.25%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SGMO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Sangamo Therapeutics, Inc. [SGMO]

Reports for Purchase

Showing records 181 - 200 ( 321 total )

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 181

02/05/2016

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 8

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 182

01/31/2016

Daily Note

Pages: 39

February and Full-Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 183

12/31/2015

Daily Note

Pages: 42

Emerging Pharmaceuticals - January and Full-Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 184

12/11/2015

Daily Note

Pages: 5

New Data Support Ongoing and Planned Gene Editing Studies in Hematopoietic Stem Cells; Reiterate OUTPERFORM and $30 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 185

12/07/2015

Daily Note

Pages: 6

Preclinical Results at ASH Bolster Sangamo''s ZFN Platform; Reiterate OUTPERFORM and $30 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 186

12/07/2015

Daily Note

Pages: 46

December 2015 and Full-Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 187

12/02/2015

Daily Note

Pages: 5

Sangamo Is Cleared to Initiate In-Vivo Human Testing of its ZFN Based Protein Replacement Platform for Hemophilia B; Reiterate OUTPERFORM and $30 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 188

11/20/2015

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 23

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 189

11/03/2015

Daily Note

Pages: 48

November and Remaining 2015 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 190

10/29/2015

Company Report

Pages: 7

Q3 Financials: Cash Balance Supports Multiple Ongoing Programs; Reiterate OUTPERFORM and $30 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 191

10/23/2015

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 26

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 192

10/04/2015

Daily Note

Pages: 45

October and 2015 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 193

10/04/2015

Daily Note

Pages: 45

October and 2015 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 194

09/11/2015

Industry Report

Pages: 5

Week Ahead in Life Sciences - Upcoming Events for the Week of September 14th

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 195

09/11/2015

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of September 14thThis report contains brief updates on the following: BIOD, CDTX, SGMO, EPZM, LXRX, NVAX, RPTP. These companies are covered in more detail in separate Daily Notes and/or Company Reports.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 196

09/02/2015

Company Report

Pages: 7

Sangamo Regains Rights to Hemophilia Program; Still on Track to Submit IND for Hemophilia B Before Year End;Reiterate OUTPERFORM and $30 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 197

08/27/2015

Industry Report

Pages: 44

September and 2015 Catalysts for Emerging PharmaceuticalsThis report contains brief updates on the following: BIOD, BMRN, CBYL, ICPT, LXRX, OMER, PCRX, RGLS, RLYP, SGMO, UTHR, VTAE, XOMA. These companies are covered in more detail in separate Daily Notes and/or Company Reports.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 198

08/27/2015

Industry Report

Pages: 44

Emerging Pharmaceuticals: September and 2015 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 199

08/21/2015

Industry Report

Pages: 6

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 200

08/21/2015

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of August 24

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party